Top Markets
#1 Black Phoenix Black Phoenix +354.04%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +69.28%
#4 Gold Park Gold Park +58.04%
#5 Acurast Acurast +39.30%
#6 OpenEden OpenEden +35.14%
#7 BasedHype BasedHype +27.14%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.38%
#9 Cryptopia Cryptopia +21.54%
#10 Avantis Avantis +17.76%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
TFF Pharmaceuticals, Inc. TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc.

TFFP
Rank in Stocks #40710
Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals,... Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection. Beyond these, the company's pipeline features other dry powder products like a cannabidiol substance targeting various epilepsy syndromes, anxiety, insomnia, and pain; an Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 patients; Niclosamide Inhalation Powder, intended for human tapeworm infections and COVID-19; and a range of other vaccines. Strategic partnerships are also central to its operations, including a licensing arrangement with the University of Texas at Austin for inhaled dry powder drug development, a joint development pact with Augmenta Bioworks, Inc. for the inhaled SARS-CoV2 monoclonal antibody, and a broad licensing and collaboration agreement with UNION therapeutics A/S. Established in 2018, the company maintains its headquarters in Austin, Texas.
Share Price
$0.065
Last synced: 2025-01-10
Market Cap
$94.10K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade TFF Pharmaceuticals, Inc. (TFFP)

Category

Healthcare
Operating Margin for TFF Pharmaceuticals, Inc. (TFFP)
Operating Margin as of 2026 TTM: 0.00%
According to TFF Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for TFF Pharmaceuticals, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.